CTLA4 and cancer: Moreover, immune checkpoint genes (such as PD1/PD-L1, LAG-3, CTLA-4, and HAVCR2) have been certified to participate in the immune suppression process of multiple tumors and targeted inhibitors have also been applied to specific immunotherapy for cancers (Zhang H. et al., 2021).